Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 389 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunizations Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Persistent Readiness Through Early Prediction Immunization Study

NCT05346302
View directory record Official record
Conditions
Inflammatory Response
Interventions
Pneumovax 23, Typhim VI, Saline
Drug · Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

NCT00006184
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide, Cyclosporine, Doxorubicin hydrochloride, Etoposide, Fludarabine phosphate, Prednisone, Vincristine Sulfate, Methotrexate, GMCSF (granulocyte macrophage colony stimulating factor), GCSF (granulocyte colony stimulating factor)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 2 Interventional

Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma

NCT00203879
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug), MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Not applicable Interventional Results available

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer

NCT00470574
View directory record Official record
Conditions
Breast Cancer
Interventions
QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, immunoenzyme technique, immunologic technique, laboratory biomarker analysis
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 22, 2026, 4:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The STOP-HPV Trial 3: Prompts Intervention

NCT03599583
View directory record Official record
Conditions
Immunization, Vaccination
Interventions
STOP-HPV prompts intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Itasca, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

NCT01756950
View directory record Official record
Conditions
Influenza
Interventions
2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020, 30 mg/kg CR8020, 50 mg/kg CR8020, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

NCT04084769
View directory record Official record
Conditions
Meningococcal Immunisation (Healthy Volunteers)
Interventions
Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
13 Years to 26 Years
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • San Diego, California • Bardstown, Kentucky + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Not applicable Interventional

Accountable Care Organizations/ Public Health Collaborative

NCT02133391
View directory record Official record
Conditions
Immunization Reminder System
Interventions
Centralized Reminder/Recall (R/R), Practice-based Reminder/Recall
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Months and older
Enrollment
78,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Not applicable Interventional Results available

Virtual Immersive Communication Training on Recommending Immunizations

NCT04368455
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Virtual Immersive Communication Training on Recommending Immunizations (VICTORI), HPV Same Way Same Day App
Behavioral
Lead sponsor
Brittany Rosen
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 3 Interventional

Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination

NCT00005758
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), HIV-1 Immunogen
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients

NCT00002248
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Cryptosporidium Immune Whey Protein Concentrate (Bovine)
Drug
Lead sponsor
Univax Biologics Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

NCT06118151
View directory record Official record
Conditions
Influenza, Influenza Immunization
Interventions
Influenza Hemagglutinin mRNA vaccine, Quadrivalent Recombinant Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
20
States / cities
Rolling Hills Estates, California • San Diego, California • Coral Gables, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 1Phase 2 Interventional

Maternal Immunization To Prevent Infant Otitis Media

NCT00617682
View directory record Official record
Conditions
Otitis Media
Interventions
PNCRM9, Placebo comparator
Biological
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years and older · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Bloomington, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Oct 22, 2026, 4:42 AM EDT
Active, not recruiting Phase 1 Interventional

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies

NCT06006546
View directory record Official record
Conditions
Chronic HIV Infection
Interventions
426c.Mod.Core-C4b, Adjuvant 3M-052-AF+Alum
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 22, 2026, 4:42 AM EDT
Recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

NCT07192458
View directory record Official record
Conditions
Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions
Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 4:42 AM EDT
Withdrawn No phase listed Observational

B-Cell Hematologic Malignancy Vaccination Registry

NCT02298816
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia, Lymphocytosis, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, Hematological Malignancies
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 22, 2026, 4:42 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

NCT07348692
View directory record Official record
Conditions
Pneumococcal Immunization, Healthy Volunteers
Interventions
PCV21 vaccine, 20vPCV licensed vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
14
States / cities
Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Vaccine for Recurrent Urinary Tract Infections in Women

NCT00261248
View directory record Official record
Conditions
Recurrent Urinary Tract Infections in Women
Interventions
Immunization with inactivated bacteria
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2003
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

NCT06698198
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
Pneumococcal Conjugate Vaccine, Prevnar 13®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
19 Years to 49 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Metairie, Louisiana • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

NCT00089193
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate

NCT06646406
View directory record Official record
Conditions
COVID-19 Immunisation, Influenza Vaccine
Interventions
Patient letter and clinician communication
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years and older
Enrollment
114,165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

NCT00004579
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
gp160 MN/LAI-2, ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 4:42 AM EDT
Completed Not applicable Interventional

Synchronized Immunization NotifiCations

NCT02710318
View directory record Official record
Conditions
Vaccination
Interventions
Electronic immunization alert
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
Up to 17 Years
Enrollment
15,348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 22, 2026, 4:42 AM EDT